In the realm of scientific achievements, few accolades carry the weight and significance of the Pathway Award bestowed by industry giants Sanofi and Regeneron. Today, we celebrate this remarkable accomplishment of our laboratory.
Type 2 inflammation plays a role in many diseases across a range of therapy areas, including dermatology, respiratory, and gastroenterology. There is a need for more research to address the wide range of debilitating conditions associated with type 2 inflammation and relieve the burden on patients and their families.
That's why Sanofi and Regeneron have launched the PATHWAYS Global Innovation Grants initiative to provide funding for independent scientific research in type 2 inflammation and its associated diseases.
The Polverino Laboratory, a renowned hub of innovation and dedication, has been at the forefront of groundbreaking research in the field of biotechnology. Their unwavering commitment to excellence and relentless pursuit of knowledge have culminated in the well-deserved recognition through the Pathway Award for COPD from Sanofi and Regeneron. This accolade stands as a testament to their pioneering work that pushes the boundaries of scientific exploration.
Our Laboratory's receipt of the Pathway Award from Sanofi and Regeneron is a celebration of the spirit of inquiry that propels us all forward. Our commitment to innovation and discovery serves as a guiding light for professionals in the field, inspiring us to aim higher and reach further in our pursuits.
コメント